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Background: Animal models have shown that glial cells (microglia and astrocytes) in the
spinal cord undergo activation following peripheral injury associated with chronic pain,
suggesting the involvement of these cells in pain diseases. We  have previously reported
that Yokukansan (YKS), a Japanese traditional herbal (Kampo) medicine, is effective against
chronic pain through the suppression of spinal glial cell activation. Morphine is a widely-
used opioid analgesic for relieving severe pain, but its repeated administration leads to the
development of antinociceptive tolerance. The development of morphine tolerance is also
reported to be caused by spinal glial cells activation. In the present study, we investigated
the  inhibitory effects of YKS on the development of morphine tolerance and the activation
of  the spinal microglia and astrocytes using a rat model.
Methods: Male Wistar rats received a subcutaneous injection of morphine hydrochloride
(10  mg/kg/d) for 7 days, and the withdrawal latency to thermal stimulation was measured
daily using a hot plate test. Thereafter, the appearance of activated microglia and astrocyte
in  the spinal cord (L5) was examined by immunoﬂuorescence staining. Ionized calcium
binding adapter molecule-1 (Iba-1) staining was used to label microglia and glial ﬁbrillaryacidic protein (GFAP) staining was performed to label astrocytes. YKS was administered
mixed with powdered rodent chow at a concentration of 3%.
Results: The preadministration of YKS (started 3 d before the morphine injection) pre-
vented the development of morphine tolerance. The repeated administration of morphine
increased Iba-1 and GFAP immune reactivities in the spinal cord; however, these activationswere inhibited by the preadministration of YKS.
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Conclusion: These results suggest that the preadministration of YKS attenuates the devel-
opment of antinociceptive morphine tolerance, and the suppression of spinal glial cell
activation may be one mechanism underlying this phenomenon.
©  2016 Korea Institute of Oriental Medicine. Published by Elsevier. This is an open access
article under the CC BY-NC-ND license1.  Introduction
Glial cells are known to release various inﬂammatory
cytokines and neurotrophic factors, such as adenosine
triphosphate, interleukin (IL) -6 and -1,  tumor necrosis fac-
tor (TNF)-, and nitric oxide, that lead to the regulation of
neuronal functions and synaptic contacts.1 Studies using ani-
mal  models have reported that the glial cells (microglia and
astrocytes) in the spinal cord undergo structural and func-
tional modiﬁcations following peripheral injuries associated
with chronic pain, suggesting the involvement of these cells in
pain.2,3 Therefore, these cells may potentially serve as targets
for pain therapy.
Morphine is an opioid analgesic widely used for relieving
severe pain such as that associated with cancer and surgery.
However, its repeated administration may lead to the devel-
opment of antinociceptive tolerance through the activation of
spinal glial cells4; the administration of glial modulators, such
as propentofylline, minocycline, and P2X4 receptor antisense
oligonucleotide, may help attenuate this.5,6
Yokukansan (Yi-Gan San; YKS), ﬁrst reported in the Bao-
ying jin-jing-lu (written in 1550), is a traditional herbal (Kampo)
medicine consisting of seven herbs (Table 1).7 YKS has been
administered to patients who show symptoms such as emo-
tional irritability, neurosis, and insomnia and to infants who
suffer from night crying and convulsions.8 However, YKS has
also recently been reported to be effective against pain disor-
ders, such as headache, post-herpetic neuralgia, ﬁbromyalgia,
and trigeminal neuralgia.9,10 Previous studies have demon-
strated the antinociceptive effects of YKS in mice models
with visceral pain11 and rat models with chronic constric-
tion injury.12,13 Moreover, Nakagawa et al14 reported that the
preadministration of YKS daily for 3 weeks attenuates mor-
phine tolerance; however, they did not discuss the mechanism
involved sufﬁciently. We have previously reported that YKS
has analgesic effects on chronic inﬂammatory pain using rat
Table 1 – Component galenicals of Yokukansan (YKS;
TJ-54)
Component galenicals of Yokukansan (YKS; TJ-54)
Uncariae cum Uncis ramulus 3.0 g
Cnidii rhizoma 3.0 g
Bupleuri radix 2.0 g
Atratylodis Lanceae rhizoma 4.0 g
Poria 4.0 g
Angelicae radix 3.0 g
Glycyrrhizae radix 1.5 g
The weights show the mixing ratio.(http://creativecommons.org/licenses/by-nc-nd/4.0/).
models with adjuvant arthritis, and one of the mechanisms
involved was the inhibitory effect of YKS on the activation of
microglial cells.15
Therefore, in the present study we  investigated the
inhibitory effect of YKS on the activation of spinal microglia
and astrocytes using a rat model with morphine tolerance.
2.  Methods
2.1.  Animals
This study used male Wistar rats (7 wk old, weighing 190–220 g)
that were purchased from Nippon Bio-Supp. Center (Tokyo,
Japan). During the study period, the animals were housed
in standard plastic cages in our animal facilities at 25 ± 2 ◦C,
55 ± 5% humidity, and a 12-hour light/dark cycle. Food and
water were provided ad libitum. All experiments were per-
formed according to the guidelines of the Committee of
Animal Care and Welfare of Showa University (certiﬁcate
number: 02028).
2.2.  Administration  of  YKS
YKS (Lot No. 2110054010; manufactured by Tsumura, Tokyo,
Japan; Table 1) was mixed with powdered rodent chow (CE-2;
CLEA Japan, Tokyo, Japan) at a concentration of 3% and fed to
the YKS-treated rats. The rats that were not treated with YKS
were fed powdered chow only. The concentration was chosen
based on effective doses of YKS recommended by previous
reports.15
2.3.  Antinociceptive  effect  of  YKS
The rats were randomly divided into a control group (Con; n = 7)
and a YKS-treated group (YKS; n = 7), and thermal hyperalgesia
was assessed daily for 10 days by measuring the withdrawal
latency using a hot plate test.16 The rats were placed on a hot
plate (Hot plate analgesia meter model 39D; IITC Life Science,
Woodland Hills, CA, USA) with the temperature adjusted to
47.5 ◦C. The latency up to the ﬁrst sign of paw licking or jump-
ing in response to the heat was measured, and 20 seconds was
considered as the cutoff point to avoid tissue damage. The
administration of YKS was started immediately after conduct-
ing the hot plate test on Day 1.
2.4.  Inﬂuence  of  YKS  on  the  antinociceptive  effect  of
morphineThis test was performed to investigate whether YKS had
any inﬂuence on the antinociceptive effect of a single mor-
phine administration. The rats were randomly divided into a
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signiﬁcantly decreased in the Mor (10.94 ± 4.01 s) and YKS +
Mor  (10.98 ± 2.50 s) groups compared with withdrawal latency
in the pre-YKS + Mor group (18.90 ± 1.10 s; p < 0.01). This. Takemoto et al/Yokukansan for Morphine Tolerance 
re-YKS + Mor  group (n = 9) and a Mor  group (n = 9). The pre-
KS + Mor  group had been administered with YKS 3 days
rior to the test. Each rat received a subcutaneous injection of
orphine hydrochloride (10 mg/kg; Takeda Chemical Indus-
ries, Osaka, Japan), and the withdrawal latency was assessed
sing a hot plate test. The measurement was performed prior
o and 30 minutes, 60 minutes, 90 minutes, 120 minutes, and
80 minutes after the administration of morphine.
.5.  Inhibitory  effect  of  YKS  on  morphine  tolerance
his test was performed to investigate whether YKS could
nhibit the development of antinociceptive tolerance to mor-
hine. The rats were randomly divided into a pre-YKS + Mor
roup (n = 9), a YKS group (n = 9), and a Mor  group (n = 9). Each
at received a subcutaneous injection of morphine hydrochlo-
ide (10 mg/kg) once daily, and the withdrawal latency was
easured after 30 minutes. The administration of YKS was
tarted 3 days prior to morphine injection in the pre-YKS +
or  group and immediately after the ﬁrst morphine injection
n the YKS group.
.6.  Changes  in  spinal  microglia  and  astrocytes
he appearance of activated microglia and astrocytes in
he spinal cord was investigated using immunoﬂuorescence
taining. Ionized calcium binding adapter molecule-1 (Iba-
) staining was used to label microglia, and glial ﬁbrillary
cidic protein (GFAP) staining was used to label astrocytes.6,13
he rats were randomly divided into the control group (n = 5),
re-YKS + Mor  group (n = 5), and Mor  group (n = 5). The con-
rol group was subcutaneously injected with physiological
aline, whereas the pre-YKS + Mor  and Mor groups were
njected with morphine hydrochloride (10 mg/kg) once daily
or 5 days. On Day 5, the rats were intraperitoneally anes-
hetized with pentobarbital sodium (50 mg/kg; Somnopentyl,
yoritsu Seiyaku, Tokyo, Japan) 30 minutes after the morphine
r saline administration and were intracardially perfused with
hosphate buffered saline (PBS) at pH 7.4 until all of the blood
ad been removed from the system. After perfusion with
% paraformaldehyde in 0.1 M PBS, the ﬁfth lumbar spinal
ords (L5) were harvested. Tissue specimens were embedded
n optimal cutting temperature (OCT) compound, frozen and
hen cut into 30 m sections using a cryostat (CM3050S; Leica
iosystems, Nussloch, Germany). The sections for microglia
taining were ﬁrst incubated overnight at 4 ◦C with rabbit anti-
ba-1 (1:500; Wako Pure Chemical Industries, Osaka, Japan)
rimary antibody and then incubated in ﬂuorescein isothio-
yanate (FITC)-conjugated goat Anti-Rabbit IgG (1:200; Jackson
mmunoResearch Laboratories, West Grove, PA, USA) for 1
our at room temperature. The sections for the astrocyte
taining were incubated overnight at 4 ◦C with mouse anti-
FAP-Cy3 antibody (C9205; 1:500, Sigma-Aldrich, St. Louis,
O, USA). The samples were observed using a confocal laser
canning ﬂuorescence microscope (FV1000D, Olympus, Tokyo,
apan), and the optical densities of immunoreactive staining
ere measured using an appropriate software program (FV10-
W, Olympus). All values were reported as an average of ten
icrographs per rat.43
2.7.  Statistical  analysis
The experimental data are shown as the mean ± standard
error of the mean (SEM). Signiﬁcant differences were evalu-
ated using a one-way analysis of variance test using SPSS for
Windows (ver. 12.0) (IBM Corporation, Armonk, NY, USA). Com-
parisons between the three groups were performed using the
post hoc Tukey test, whereas the Student t test was used for
comparisons between the two groups. A p value < 0.05 was
considered to be statistically signiﬁcant.
3.  Results
3.1.  Antinociceptive  effect  of  YKS  upon  thermal
stimulation
YKS was administered for 10 days, and the withdrawal latency
was measured daily. No signiﬁcant differences were observed
between the two groups (Fig. 1). Thus, YKS did not increase
the withdrawal threshold value in intact rats.
3.2.  Inﬂuence  of  YKS  on  antinociceptive  effects  of
morphine
The inﬂuence of YKS on the antinociceptive effects of a single
morphine administration was examined, and the withdrawal
latencies were observed to increase after 120 minutes in both
groups and return to the same level as before administra-
tion, after 180 minutes (Fig. 2). No signiﬁcant differences were
observed between the two groups during this period. There-
fore, YKS did not prolong the reaction duration of morphine.
3.3.  Inhibitory  effect  of  YKS  on  morphine  tolerance
We  also examined if the administration of YKS  had any
inﬂuence on the antinociceptive effect of daily morphine
administration (Fig. 3). On Day 3, the withdrawal latenciesFig. 1 – Antinociceptive effect of Yokukansan (hot plate
test). Yokukansan was administered for 10 days, and it did
not increase the withdrawal latency in intact rats.
Con, control group; YKS, Yokukansan-treated group.
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Fig. 2 – Inﬂuence of Yokukansan on antinociceptive effect
of morphine (hot plate test). Reaction duration of morphine
lasted for 120 minutes, and Yokukansan did not have any
inﬂuence on the antinociceptive effect of morphine.
Mor,  morphine-treated group; pre-YKS + Mor,
Yokukansan-pre-treated + morphine-treated group.
signiﬁcant difference persisted even on Day 7 (the Mor group:
6.41 ± 1.45 s, the YKS + Mor  group: 5.34 ± 0.81 s, the pre-YKS +
Mor  group: 9.15 ± 3.36 s; p < 0.05). Therefore, preadministration
may help prevent the development of morphine tolerance.
3.4.  Changes  in  spinal  glial  cells
3.4.1.  Changes  in  spinal  microglia
The Iba-1 immunoreactivity was assessed in the spinal cord
(L5) (Fig. 4), and the images of the spinal dorsal horns are
shown in Fig. 4A–4F. The number of Iba-1-positive cells in the
Fig. 3 – Inhibitory effect of Yokukansan (YKS) on morphine
tolerance. From Day 3 to Day 7, the decrease in withdrawal
latency was signiﬁcantly inhibited in the pre-YKS + Mor
group in comparison with that in the Mor  and YKS + Mor
groups (Days 3–6: p < 0.01, Day 7: p < 0.05). Preadministration
could prevent the development of morphine tolerance.
* p < 0.05 (vs. Mor,  YKS + Mor).
† p < 0.01 (vs. Mor,  YKS + Mor).
Mor,  morphine-treated group; pre-YKS + Mor,
Yokukansan-pretreated + morphine-treated group; YKS +
Mor,  Yokukansan-treated + morphine-treated group.Integr Med Res (  2 0 1 6 ) 41–47
Mor group increased (Fig. 4B) in comparison with that in the
control group (Fig. 4A) and the pre-YKS + Mor group (Fig. 4C;
200× magniﬁcation). The Iba-1 values were then expressed as
optical densities (Fig. 4G). Ten images (at 2 m intervals) were
recorded per rat, the immune reactivities were quantiﬁed,
and all the values were reported as an average of ten micro-
graphs per rat. The Iba-1 level was signiﬁcantly increased
in the Mor  group (231.1 ± 28.2 immunoreactivity (IR) density)
compared with that in the control group (143.0 ± 59.3 IR den-
sity; p < 0.05). This increase was signiﬁcantly inhibited in the
pre-YKS + Mor group (151.3 ± 44.0 IR density; p < 0.05). Further-
more,  microgliosis was conﬁrmed in the image  (600×) of the
Mor group (Fig. 4E) based on intense Iba-1 immunoreactivity,
large cell bodies, and short or thick processes of microglia.
However, this change was suppressed in the pre-YKS + Mor
group (Fig. 4F).
3.4.2.  Changes  in  spinal  astrocytes
The GFAP immunoreactivity was assessed in the spinal cord
(L5; Fig. 5), and the images of the spinal dorsal horns are
shown in Fig. 5A–F. The Mor  group showed an increase in
the number of GFAP-positive cells (Fig. 5B) when compared
with the control group (Fig. 5A) and the pre-YKS + Mor  group
(Fig. 5C; 200× magniﬁcation). The GFAP values were then
expressed as optical densities (Fig. 5G). The GFAP level was
signiﬁcantly increased in the Mor group (714.8 ± 255.7 IR den-
sity) compared with that in the control group (228.1 ± 45.5 IR
density; p < 0.05). This increase was signiﬁcantly inhibited in
the pre-YKS + Mor group (326.0 ± 104.2 IR density; p < 0.05).
Furthermore, astrogliosis was conﬁrmed in the image  (600×)
of the Mor group (Fig. 5E) based on intense GFAP immunore-
activity and hypertrophied astrocytes with thick processes.
However, this change was suppressed in the pre-YKS + Mor
group (Fig. 5F).
4.  Discussion
The present study indicates that the administration of YKS
does not have any apparent antinociceptive effects and does
not prolong the reaction duration of morphine. However, the
preadministration of YKS may inhibit the development of
antinociceptive tolerance to morphine. It is believed that YKS
prevents a decrease in pain threshold by improving pathologic
changes, although YKS does not increase withdrawal latency
in the physiological state. Nakagawa et al14 reported that the
repeated preadministration of YKS for 3 weeks prevented the
development of morphine tolerance and physical dependence
in mice. In this study, preadministration for 3 days affected the
development of morphine tolerance, although no such effects
could be seen in rats simultaneously administered with YKS
and morphine. The reason for this is still unclear, and further
studies are warranted.
Morphine tolerance is a complex physiological response
involving glial cell activity,4–6 neuroinﬂammation,17,18 and
the activation of spinal N-Methyl-D-Aspartate (NMDA)
receptors.19 Many  studies report that glial cells may be
involved in the development of antinociceptive tolerance
to morphine, and glial activation inhibitors (such as P2X4
receptor antagonist, P2X4 receptor antisense, minocycline,
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Fig. 4 – Inhibitory effect of Yokukansan (YKS) on microglia activation induced by morphine treatment. (A–C) 200×
magniﬁcation; scale bar = 100 m.  (D–F) 600× magniﬁcation; scale bar = 20 m.  (A–F) Ionized calcium binding adapter
molecule-1 (Iba-1) staining of the L5 spinal dorsal horn on Day 5 following morphine or saline treatment, and (G) the
ﬂuorescence density quantiﬁcation of Iba-1 immune reactivity. Iba-1 expression in (B) the Mor  group increased signiﬁcantly
compared with that in (A) the control group; however, this increase was inhibited in (C) the pre-YKS + Mor  group. (E) In the
Mor  group, microgliosis (yellow arrow) was conﬁrmed based on intense Iba-1 immunoreactivity, large cell bodies, and the
short or thick processes of microglia; however, this change was suppressed in (F) the pre-YKS + Mor  group.
* p < 0.05.
Con, control group; Iba-1, ionized calcium binding adapter molecule-1; IR, immunoreactivity; Mor,  morphine-treated group;
pre-YKS + Mor,  Yokukansan-pre-treated + morphine-treated group.
Fig. 5 – Inhibitory effect of Yokukansan on astrocyte activation induced by morphine treatment. (A–C) 200× magniﬁcation;
scale bar = 100 m.  (D–F) 600× magniﬁcation; scale bar = 20 m.  (A–F) Glial ﬁbrillary acidic protein (GFAP) staining of the L5
spinal dorsal horn on Day 5 following morphine or saline treatment, and (G) the ﬂuorescence density quantiﬁcation of GFAP
immune reactivity. GFAP expression in (B) the Mor  group increased signiﬁcantly compared with that in (A) the control group;
however, this increase was inhibited in (C) the pre-YKS + Mor  group. (E) In the Mor group, astrogliosis (yellow arrow) was
conﬁrmed based on intense GFAP immunoreactivity and hypertrophied astrocytes with thick processes; however, this
change was suppressed in (F) the pre-YKS + Mor  group.
* p < 0.05.
Con, control group; GFAP, glial ﬁbrillary acidic protein; IR, immunoreactivity; Mor,  morphine-treated group; pre-YKS + Mor,
Yokukansan-pre-treated + morphine-treated group.
r46  
propentofylline, and pentoxifylline) delay the development
of this tolerance.5,6 Pentoxifylline is known to be a cytokine
inhibitor that decreases the levels of TNF-, IL-1, and IL-6.20
A clinical study reported that pentoxifylline enhances the
effects of morphine after surgery, and patients who received
preoperative pentoxifylline had lower opioid requirements
and serum levels of IL-6 compared with those in the control
group.21 Ebisawa et al13 reported that YKS improves mechan-
ical allodynia through the regulation of IL-6 expression in
microglia and astrocytes in the spinal cord.
The activation of the spinal NMDA  receptor, a glutamate
receptor found in nerve cells, also plays a crucial role in
the development of morphine tolerance,19 and a pharma-
cological blockade of these receptors may attenuate this.22
Moreover, the activation of central NMDA  receptors is involved
in microglial activation, and they can be inhibited by MK-801
(an NMDA  receptor antagonist).23 Kawakami et al24 reported
that YKS includes isoliquiritigenin, which is known to act as
an NMDA  receptor antagonist. In this study, immune reactiv-
ities of Iba-1, a marker of microglia, and GFAP, a marker of
astrocytes, increased with the development of morphine tol-
erance. This was in accordance with past reports.4–6 However,
these increases were controlled by the preadministration of
YKS. The inhibitory effects of YKS on IL-6 expression and the
antagonistic action of NMDA  receptors may be responsible for
this. We  will investigate the role of IL-6 and NMDA  receptors
in the effects of YKS on antinociceptive tolerance to morphine
in the future.
To the best our knowledge, this study is the ﬁrst to exam-
ine the relationship between YKS and glial cell activation
in morphine tolerance. The combined administration of YKS
and morphine may attenuate morphine tolerance. Several
other studies have recently been conducted to clarify the
pharmacological actions of YKS, and they reported an ame-
liorative effect on glutamate clearance in astrocytes.25 In the
serotonin-responsive nervous system, YKS has a partial ago-
nistic effect on the serotonin 1A receptor, which is associated
with analgesia,26 and a downregulatory effect on the serotonin
2A receptor, which is associated with pain.27 Further studies
are needed to understand the mechanism of the effects of YKS
on antinociceptive tolerance to morphine so as to allow its
effective use in patients.
This study suggests that the preadministration of YKS
attenuates the development of antinociceptive morphine tol-
erance, and the suppression of spinal glial cell activation may
be one mechanism underlying this phenomenon.
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